CNS Clinical Trials
Suicidality and Data Collection: Workshop Summary
Price for Eshop: 634 Kč (€ 25.4)
VAT 0% included
New
E-book delivered electronically online
E-Book information
Annotation
The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Ask question
You can ask us about this book and we'll send an answer to your e-mail.